Boehringer Breathes Easy Over Spiriva Patent Expiry In US

The German group's pharma chief told Scrip that he does not expect to see any competition in the US in the short term to the soon-to-be off-patent COPD blockbuster, citing the complicated case of GSK's Advair for which there are still no FDA approved generics despite losing exclusivity a while ago.